retinitis pigmentosa
Conditions
Interventions
Treated group: oral administration of nilvadipine 4mg per day
Control group: herenien, tocoferol or no medication as patients'
requests
Sponsors
Department of Ophthalmology, Hirosaki University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Fundus examination showing typical features of retinitis pigmentosa. Rod-cone degeneration type with rod-predominant degeneration shown on electroretinography and/or subjective symptomes. Constriction of visual field defects evaluated by either Golfmann perimetry or a Humphrey Visual Field Analyzer. Residual central visual field better than -35.0dB as evaluated by the 10-2 SITA FAST program Best corrected visual acuity better than 0.1
Exclusion criteria
Exclusion criteria: Cataract extraction or other intraocular surgery during observation periods Systolic blood pressure less than 110 mmHg Presence of cataract or other media opacities that would disturb fundus examination and/or visual field examination Use of other calcium antagonists to treat systemic illnesses Pigmented retinal degeneration secondary to inflammation or presence of ocular diseases other than retinitis pignebtosa
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To clarify if the degrees in progression of visual field defect are different between patients with retinitis pigmentosa who take nilvadipine for 30 months and those who do not. | — |
Secondary
| Measure | Time frame |
|---|---|
| To clarify if the degrees in progression of visual field defect are different between patients with retinitis pigmentosa who take nilvadipine for longer than 30 months and those who do not. | — |
Countries
Japan
Contacts
Public ContactMitsuru Nakazawa
Hirosaki University Graduate School of Medicine Department of Ophthalmology
Outcome results
None listed